Compare Page
GHRP-6 vs Hexarelin
Quick verdict: GHRP-6 and Hexarelin are both growth hormone releasing peptides from the same GHRP class, acting on the ghrelin receptor (GHS-R1a). Hexarelin is the most potent GHRP by weight, producing the largest GH pulses, but also carries the strongest cortisol and prolactin elevation. GHRP-6 is slightly less potent but offers significant appetite stimulation and documented cardioprotective properties that distinguish it within the class.
Read the full peptide profiles: GHRP-6 | Hexarelin.
At a Glance: GHRP-6 vs Hexarelin
Mechanism of Action
GHRP-6 and Hexarelin belong to the same peptide class — synthetic hexapeptide growth hormone secretagogues that activate the ghrelin receptor (GHS-R1a) on somatotroph cells in the anterior pituitary. Both peptides stimulate pulsatile growth hormone release through a mechanism distinct from GHRH, allowing synergistic effects when combined with GHRH-class compounds. However, their pharmacological profiles differ in potency, receptor selectivity, and off-target effects, making them distinct research tools despite their shared class membership.
Hexarelin is consistently reported as the most potent GHRP in terms of peak GH elevation per microgram. It produces robust GH pulses but also carries the strongest cortisol and prolactin co-stimulation of any GHRP. A unique feature of Hexarelin is its binding to CD36 (scavenger receptor class B), a cardiac receptor implicated in fatty acid metabolism and cardioprotection. This CD36 interaction is independent of GH release and has led to dedicated research into Hexarelin’s cardioprotective properties, including reduction of cardiac fibrosis and protection against ischaemia-reperfusion injury in animal models.
GHRP-6, while less potent than Hexarelin for peak GH output, produces strong appetite stimulation through its ghrelin-mimetic activity in the hypothalamus. This appetite-driving effect is more pronounced with GHRP-6 than with Hexarelin, likely reflecting differences in hypothalamic receptor binding dynamics. GHRP-6 also shows cardioprotective effects but through different pathways — its cardiac benefits appear more related to general GHS-R1a signalling rather than the CD36-mediated mechanism characteristic of Hexarelin. Both peptides are subject to desensitisation with chronic high-dose use, though Hexarelin may show faster tachyphylaxis. For comparisons with the selective secretagogue Ipamorelin, see GHRP-6 vs Ipamorelin and Hexarelin vs Ipamorelin.
Research Evidence
GHRP-6 has one of the longest research histories of any synthetic secretagogue, with Bowers’ original characterisation in the 1980s establishing the GHRP class. Decades of pharmacological studies have mapped its dose-response curves, receptor binding kinetics, and hormonal cross-reactivity in both animal and human subjects. GHRP-6 has been particularly useful in neuroendocrine research as a diagnostic tool for GH deficiency, and its appetite-stimulating properties have been investigated in cachexia and muscle-wasting contexts.
Hexarelin’s research trajectory has focused more on two areas: raw GH-releasing potency and cardiac effects. The cardiac research line is distinctive — Bhogendra et al. and others have shown that Hexarelin protects cardiac tissue via CD36 receptor activation, reducing apoptosis and fibrosis in animal ischaemia models. Clinical studies in healthy volunteers and GH-deficient patients have confirmed Hexarelin’s GH-releasing superiority over GHRP-6, but also documented its more pronounced cortisol and prolactin stimulation. Notably, Hexarelin appears more susceptible to tachyphylaxis (GH response attenuation) with repeated administration than GHRP-6, which may limit its utility in chronic research protocols.
Both peptides share the limitation of non-selectivity — they stimulate multiple hormonal axes beyond GH. This makes them less suitable for research requiring isolated GH elevation compared to Ipamorelin, but their broader pharmacological effects make them valuable tools for studying the ghrelin system, appetite regulation, and cardiac physiology. See also Hexarelin vs GHRP-2 for the third major GHRP comparison.
Key Differences
- GH potency: Hexarelin produces higher peak GH levels than GHRP-6 at comparable doses, making it the most potent GHRP by weight
- CD36 binding: Hexarelin uniquely binds CD36 cardiac receptors, producing cardioprotective effects independent of GH release — GHRP-6 does not share this mechanism
- Appetite stimulation: GHRP-6 produces more pronounced appetite stimulation than Hexarelin, making it more relevant in cachexia and wasting research
- Tachyphylaxis: Hexarelin shows faster desensitisation of GH response with chronic use; GHRP-6 maintains its response more consistently over time
- Half-life: Hexarelin has a longer circulating half-life (~70 min vs ~20–30 min), influencing dosing frequency in research protocols
- Cortisol/prolactin elevation: Both raise cortisol and prolactin, but Hexarelin’s effect is more pronounced, potentially complicating research designs sensitive to HPA axis perturbation
Frequently Asked Questions
Which GHRP produces the most growth hormone?
Hexarelin consistently produces the highest peak GH concentration among the GHRP family in comparative studies, followed by GHRP-2, then GHRP-6. However, raw potency isn’t the only consideration — Hexarelin also produces the most cortisol and prolactin co-stimulation and is most susceptible to tachyphylaxis.
Does Hexarelin have cardioprotective effects that GHRP-6 doesn’t?
Hexarelin has a unique cardioprotective mechanism through CD36 receptor binding that is not shared by GHRP-6. This scavenger receptor interaction protects against cardiac ischaemia-reperfusion injury and reduces fibrosis independently of GH release. GHRP-6 does show some cardiac benefits, but these appear to be mediated through general GHS-R1a signalling rather than CD36-specific pathways.
Why does Hexarelin stop working over time?
Hexarelin is more prone to tachyphylaxis (diminishing GH response with repeated dosing) than other GHRPs. This appears related to downregulation of GHS-R1a expression at the pituitary level. GHRP-6 shows less pronounced desensitisation, making it more suitable for chronic research protocols. Pulsatile dosing strategies with rest periods can partially mitigate tachyphylaxis for both peptides.
Do both GHRP-6 and Hexarelin raise cortisol?
Yes, both peptides stimulate ACTH and cortisol release alongside GH, though Hexarelin produces a more substantial cortisol elevation at GH-effective doses. This non-selective hormonal stimulation is a key disadvantage of both peptides compared to selective secretagogues like Ipamorelin, which does not significantly affect the HPA axis.
Can GHRP-6 or Hexarelin be combined with GHRH analogs?
Both peptides synergise with GHRH analogs such as CJC-1295 or Sermorelin. The combination produces GH output significantly greater than either peptide alone because GHRPs (ghrelin pathway) and GHRH analogs (GHRH receptor pathway) act through independent mechanisms on the somatotroph cell. This synergy is well-documented for both GHRP-6 and Hexarelin in clinical pharmacology studies.
Is GHRP-6 better than Hexarelin for appetite stimulation?
Yes — GHRP-6 produces stronger appetite stimulation than Hexarelin. This reflects GHRP-6’s more pronounced activation of hypothalamic feeding centres through its ghrelin-mimetic activity. In research contexts where appetite stimulation is desirable (such as cachexia models), GHRP-6 is the preferred GHRP. Where appetite stimulation is unwanted, neither GHRP-6 nor Hexarelin is ideal — Ipamorelin would be the alternative choice.
Are GHRP-6 and Hexarelin banned in sport?
Yes — both are prohibited at all times by WADA under category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Anti-doping laboratories have validated detection methods for both peptides and their metabolites in urine samples.
References
- Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545. PMID: 6714155
- Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. Eur J Endocrinol. 1997;136(5):445-460. PMID: 9186261
- Bodart V, Febbraio M, Bhogendra RJ, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res. 2002;90(8):844-849. PMID: 11988484
- Locatelli V, Rossoni G, Schweiger F, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999;140(9):4024-4031. PMID: 10465271
- Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab. 2001;86(3):1169-1174. PMID: 11238504
- Popovic V, Damjanovic S, Micic D, et al. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection. J Clin Endocrinol Metab. 1995;80(3):942-947. PMID: 7883856